4,605 Shares of Bio-Rad Laboratories, Inc. $BIO Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,605 shares of the medical research company’s stock, valued at approximately $1,739,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its holdings in shares of Bio-Rad Laboratories by 57.8% during the second quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock worth $68,478,000 after buying an additional 85,393 shares in the last quarter. Wellington Management Group LLP acquired a new stake in Bio-Rad Laboratories during the second quarter worth approximately $17,690,000. Hound Partners LLC boosted its position in Bio-Rad Laboratories by 125.9% during the first quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock worth $27,241,000 after acquiring an additional 54,456 shares during the last quarter. Amundi grew its stake in Bio-Rad Laboratories by 1,763.4% in the 1st quarter. Amundi now owns 38,778 shares of the medical research company’s stock worth $10,809,000 after acquiring an additional 36,697 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in Bio-Rad Laboratories in the 1st quarter valued at $5,098,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $366.60 on Monday. The stock’s 50-day moving average is $373.01 and its 200-day moving average is $317.45. The company has a market cap of $9.86 billion, a price-to-earnings ratio of 9.65 and a beta of 1.06. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.18 and a quick ratio of 2.37. Bio-Rad Laboratories, Inc. has a 12 month low of $236.73 and a 12 month high of $396.23.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical research company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.23 by $0.42. The business had revenue of $656.40 million during the quarter, compared to analysts’ expectations of $649.94 million. Bio-Rad Laboratories had a return on equity of 3.58% and a net margin of 39.45%. The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.26 EPS. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.71 earnings per share for the current year.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, COO Jonathan P. Divincenzo sold 919 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $390.47, for a total transaction of $358,841.93. Following the completion of the sale, the chief operating officer directly owned 1,962 shares in the company, valued at $766,102.14. The trade was a 31.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP James Barry sold 1,400 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $385.63, for a total transaction of $539,882.00. Following the completion of the sale, the executive vice president directly owned 625 shares of the company’s stock, valued at $241,018.75. The trade was a 69.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,221 shares of company stock valued at $1,247,049 over the last ninety days. Corporate insiders own 30.34% of the company’s stock.

Wall Street Analyst Weigh In

BIO has been the topic of several analyst reports. Royal Bank Of Canada raised their price objective on Bio-Rad Laboratories from $390.00 to $440.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Wells Fargo & Company increased their target price on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Citigroup upped their price objective on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $366.67.

Check Out Our Latest Analysis on BIO

Bio-Rad Laboratories Company Profile

(Free Report)

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.

Further Reading

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.